Design, synthesis and anticancer evaluation of chrysin-1,3,5-triazine derivatives.

Breast cancer is the most frequently diagnosed malignancy in women and a primary contributor to cancer-related mortality worldwide. Despite significant advances in treatment, a substantial number of patients with metastatic breast cancer remain unresponsive to treatment. Accordingly, we prepared multiple chrysin-based triazine compounds to assess their anti-proliferative activity against human malignancies, particularly targeting breast cancer cell apoptosis and the related molecular pathways. demonstrated potent inhibition of breast cancer cell proliferation, colony formation, migration, adhesion, and invasion, and induced apoptosis. Additionally, RQ-6 modulated the levels of apoptosis-related proteins and transcriptomically suggested the activation of pathways such as caspase-3, p53, and TNF. In conclusion, demonstrates notable antineoplastic efficacy in breast cancer cell lines and shows promise as a candidate for further investigation as a therapeutic intervention in breast cancer. Future studies are warranted to confirm the selectivity and potential of this compound.